Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 11/20 | 0.90 |
| ▸ | JAK2 | O60674 | 7/20 | 0.90 |
| ▸ | MAP4K3 | Q8IVH8 | 7/20 | 0.90 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.90 |
| ▸ | JAK3 | P52333 | 4/20 | 0.90 |
| ▸ | JAK1 | P23458 | 3/20 | 0.90 |
| ▸ | TYK2 | P29597 | 3/20 | 0.90 |
| ▸ | PLK4 | O00444 | 2/20 | 0.90 |
| ▸ | AURKA | O14965 | 2/20 | 0.90 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.90 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.90 |
| ▸ | ABL1 | P00519 | 2/20 | 0.90 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.90 |
| ▸ | INSR | P06213 | 2/20 | 0.90 |
| ▸ | LCK | P06239 | 2/20 | 0.90 |
| ▸ | FES | P07332 | 2/20 | 0.90 |
| ▸ | CSF1R | P07333 | 2/20 | 0.90 |
| ▸ | LYN | P07948 | 2/20 | 0.90 |
| ▸ | RET | P07949 | 2/20 | 0.90 |
| ▸ | IGF1R | P08069 | 2/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3243547 | 1.00 | MET (0.90) | METJAK2MAP4K3ALKJAK3 | |
| Acetic Acid SCHEMBL16324188 | 0.95 | MET (0.82) | METJAK2MAP4K3ALKJAK3 | |
| Crizotinib SCHEMBL28844303 | 0.95 | MET (1.00) | METJAK2MAP4K3ALKJAK3 | |
| Crizotinib SCHEMBL30129754 | 0.95 | MET (1.00) | METJAK2MAP4K3ALKJAK3 | |
| Crizotinib SCHEMBL94020 | 0.95 | MET (1.00) | METJAK2MAP4K3ALKJAK3 | |
| Crizotinib SCHEMBL29831970 | 0.95 | MET (1.00) | METJAK2MAP4K3ALKJAK3 | |
| Crizotinib SCHEMBL28844302 | 0.95 | MET (1.00) | METJAK2MAP4K3ALKJAK3 | |
| Crizotinib SCHEMBL29351506 | 0.95 | MET (1.00) | METJAK2MAP4K3ALKJAK3 | |
| Crizotinib SCHEMBL93829 | 0.95 | MET (1.00) | METJAK2MAP4K3ALKJAK3 | |
| Crizotinib SCHEMBL29622387 | 0.95 | MET (1.00) | METJAK2MAP4K3ALKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288086-A1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2014-09-25 | — | — | US | claimed |
| EP-1786785-B9 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER (US) | 2013-05-22 | — | — | EP | claimed |
| US-20120263706-A1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. | 2012-10-18 | — | — | US | claimed |
| US-20100324061-A1 | including crizotinib which is 3-[(R)-1-(2-chloro-3,6-difluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; c-met inhibitors; hepatocyte growth factor (HGF) receptor (c-MET) receptor tyrosine kinase (RTK) | AGOURON PHARMACEUTICALS, INC. | 2010-12-23 | — | — | US | claimed |
| EP-1786785-B1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER (US) | 2010-04-07 | — | — | EP | claimed |
| EP-1786785-A2 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | Pfizer, Inc. (US) | 2007-05-23 | — | — | EP | claimed |
| US-20060046991-A1 | Crizotinib, a c-Met protein kinase inhibitor anticancer agent; 3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine is crizotinib | AGOURON PHARMACEUTICALS, INC. | 2006-03-02 | — | — | US | claimed |
| WO-2006021884-A2 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2006-03-02 | — | — | WO | claimed |
| EP-2315601-B1 | COMBINATION OF A C-MET ANTAGONIST AND AN AMINOHETEROARYL COMPOUND FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2018-02-14 | — | — | EP | disclosed |
| US-9375425-B2 | Combination of a C-Met antagonist and an aminoheteroaryl compound for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2016-06-28 | — | — | US | disclosed |
| US-20150250780-A1 | COMBINATION OF A C-MET ANTAGONIST AND AN AMINOHETEROARYL COMPOUND FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2015-09-10 | — | — | US | disclosed |
| US-9011865-B2 | Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer | Pierre Gabre Medicament (FR) | 2015-04-21 | — | — | US | disclosed |
| WO-2014203177-A1 | AMORPHOUS (R) -3- [1- (2, 6-DICHLORO-3-FLUOROPHENYL) METHOXY] -5- [1- (PIPERIDIN-4- YL) -1H-PYRAZOL-4-YL] PYRIDIN-2-AMINE | SHILPA MEDICARE LIMITED (IN) | 2014-12-24 | — | — | WO | disclosed |
| US-20140288086-A1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2014-09-25 | — | — | US | disclosed |
| EP-1784396-A2 | PYRAZOLE-SUBSTITUTED AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | Pfizer, Inc. (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20060276450-A1 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2006-12-07 | — | — | US | disclosed |
| US-20060128724-A1 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| US-20060046991-A1 | Crizotinib, a c-Met protein kinase inhibitor anticancer agent; 3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine is crizotinib | AGOURON PHARMACEUTICALS, INC. | 2006-03-02 | — | — | US | disclosed |
| WO-2006021884-A2 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021881-A2 | PYRAZOLE-SUBSTITUTED AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276450-A1 | Isoquinoline potassium channel inhibitors | KCNQ1, KCNQ2, KCNJ2 | MET 4877/4885JAK2 3605/4885MAP4K3 407/4885 |
| US-20060128724-A1 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP3K15, MAP3K19 | MET 1/4885JAK2 249/4885MAP4K3 10/4885 |
| US-20060046991-A1 | Crizotinib, a c-Met protein kinase inhibitor anticancer agent; 3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine is crizotinib | ALK, MET, ERBB2 | MET 2/4885JAK2 192/4885MAP4K3 78/4885 |
| US-20100324061-A1 | including crizotinib which is 3-[(R)-1-(2-chloro-3,6-difluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; c-met inhibitors; hepatocyte growth factor (HGF) receptor (c-MET) receptor tyrosine kinase (RTK) | MET, HGF, ALK | MET 1/4885JAK2 97/4885MAP4K3 147/4885 |
| US-20120263706-A1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | MET, MAP3K15, MAP3K1 | MET 1/4885JAK2 350/4885MAP4K3 24/4885 |
| US-20150250780-A1 | COMBINATION OF A C-MET ANTAGONIST AND AN AMINOHETEROARYL COMPOUND FOR THE TREATMENT OF CANCER | MET, HGF, EGFR | MET 1/4885JAK2 330/4885MAP4K3 1607/4885 |
| US-20140288086-A1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | MET, MAP3K15, MAP3K1 | MET 1/4885JAK2 350/4885MAP4K3 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.